Moderate alcohol intake does not typically interfere with the effectiveness of Stendra, but excessive consumption can diminish erectile response and increase the likelihood of dizziness. Patients are advised to drink responsibly and to be aware of how alcohol affects them personally.
Stendra (avanafil) has a rapid onset of action, often working within 15 minutes, whereas some other PDE5 inhibitors may require 30 minutes to an hour. All share a similar mechanism-PDE5 inhibition-but differ in pharmacokinetic profiles, dosing flexibility, and side-effect incidence. Clinical choice should be guided by individual response and physician recommendation.
The therapeutic effect can last up to 6 hours, allowing for sexual activity within that window. Effectiveness may vary based on dose, food intake, and individual metabolism.
Yes. Stendra is classified as a prescription-only medicine (POM) in the United Kingdom, and it can only be dispensed with a valid prescription from a licensed prescriber.
Men with diabetes often experience erectile dysfunction and may benefit from Stendra, provided they have no contraindicating conditions such as severe cardiovascular disease or nitrate use. Blood glucose control and overall health should be discussed with a healthcare professional.
A erection lasting longer than 4 hours (priapism) is a medical emergency. Seek immediate care at an emergency department; timely treatment reduces the risk of permanent tissue damage.
Some herbal products, such as ginkgo biloba or St. John’s wort, can affect cytochrome P450 enzymes and potentially alter avanafil levels. Patients should disclose all supplements to their prescriber to evaluate possible interactions.
PDE5 inhibitors can cause modest reductions in blood pressure. If you are on antihypertensive medication, especially alpha-blockers or certain vasodilators, close monitoring of blood pressure is advisable when starting Stendra.
While occasional exposure to moisture is unlikely to damage the tablets, the bathroom environment can become humid and warm, which may affect stability. It is best to store Stendra in a cool, dry place such as a bedroom drawer or a medicine cabinet away from the bathtub.
When traveling, keep Stendra in its original packaging with the prescription label visible to satisfy customs or security checks. Avoid exposure to extreme temperatures (e.g., leaving tablets in a hot car) and ensure you have an adequate supply for the duration of the trip.
Stendra is a prescription medication marketed in the United Kingdom for the treatment of erectile dysfunction (ED). Its active ingredient is avanafil, a phosphodiesterase type 5 (PDE5) inhibitor that helps achieve and maintain an erection sufficient for sexual activity. Stendra is supplied as a pill in three strengths: 50 mg, 100 mg, and 200 mg. In the UK, the medication is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and requires a prescription from a qualified healthcare professional.
Avanafil belongs to the PDE5 inhibitor class. In the penile tissue, nitric oxide released during sexual stimulation activates the enzyme guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP). Elevated cGMP relaxes smooth muscle and allows blood to flow into the corpora cavernosa, producing an erection. PDE5 normally degrades cGMP; avanafil binds to PDE5 and slows this degradation, sustaining higher cGMP levels.
Key pharmacologic features:
Stendra is approved by the MHRA for the treatment of erectile dysfunction in adult men. ED is defined as the inability to achieve or sustain an erection adequate for satisfactory sexual performance. The medication is intended for use only when sexual stimulation is present; it does not cause spontaneous erections.
Typical patient populations include:
Absolute contraindications
Known hypersensitivity to avanafil or any of the tablet’s inactive ingredients.
Concomitant use of nitrates (e.g., nitroglycerin, isosorbide dinitrate) in any form, including topical preparations, because the combination can cause severe hypotension.
Use of guanylate cyclase stimulators (e.g., riociguat) for pulmonary hypertension, which also interact with PDE5 inhibition.
Relative contraindications
Severe uncontrolled hypertension (systolic ≥ 180 mmHg or diastolic ≥ 110 mmHg).
Recent (within 30 days) myocardial infarction or stroke.
Significant hepatic impairment (Child-Pugh class C) or severe renal impairment (creatinine clearance < 30 mL/min).
Retinitis pigmentosa or other inherited retinal disorders, due to theoretical risk of visual disturbances.
These effects are generally self-limiting and do not require medical attention unless they persist or worsen.
Dosing should be individualized; the timing of the dose can be adjusted between 15 minutes and 6 hours before sexual activity, based on personal response.
If a dose is missed, do not take an extra tablet later in the day. Instead, wait until the next appropriate opportunity and resume the usual dosing schedule.
Symptoms of overdose may include severe hypotension, dizziness, or prolonged erection. If overdose is suspected, seek emergency medical attention. Management is supportive; there is no specific antidote.
Stendra does not require tapering. The medication can be stopped abruptly without withdrawal symptoms. However, patients should discuss any change in therapy with their prescriber.
This article provides educational information about Stendra and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
